Alvotech and DKSH partner to bring key biosimilar to Asia

24 Mar 2020

Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.

Alvotech Hf and DKSH have entered into an exclusive license partnership for the commercialization of AVT02, an adalimumab biosimilar, in selected Aisa Pacific (APAC) markets.

Alvotech and DKSH partner to bring key biosimilar to Asia

AVT02 is a biosimilar monoclonal antibody to AbbVie’s Humira, which is a leading drug indicated for the treatment of several autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease.

With recorded sales of approximately US$20 billion in 2018, Humira is the largest-selling blockbuster medicine worldwide.

It neutralizes Tumor Necrosis Alpha (TNF-α), which is a cytokine involved in the systemic inflammation associated with the labelled indications.

Under the partnership, Alvotech Hf will be responsible for the development and supply of AVT02, while DKSH will be responsible for its registration and commercialization.

AVT02 will be filed in the second half of 2020 with the European Medicines Agency and with US Food and Drug Administration (through Alvotech Hf’s US affiliate).

Bijay Singh, Global Head of Business Unit Healthcare, DKSH, said: “We see this partnership with Alvotech as a great opportunity to accelerate our development in the biosimilar space and strengthen our position in this fast-growing segment with tremendous promise across Asia.”

Read More

Related news

Changes needed to prevent controversial pay-for-delay pharma deals

Changes needed to prevent controversial pay-for-delay pharma deals

26 May 2020

Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.

Read more 
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

26 May 2020

SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.

Read more 
AbCellera and Lilly seal multi-year antibody discovery collaboration

AbCellera and Lilly seal multi-year antibody discovery collaboration

25 May 2020

AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.

Read more 
HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

25 May 2020

The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad launches anti-certolizumab pegol antibodies

5 May 2020

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

Read more 
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

Read more